MedTrace Logo

Cytoreductive Gastrectomy After Systemic Therapy Versus Systemic Therapy Alone For Limited Metastasis Gastric Cancer

NCT06768463 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2025-08-27

No results posted yet for this study

Summary

The results of the current studies to determine the optimal strategy for metastatic gastric cancer remain contrversial worldwide.

Hypothesis: Cytoreductive Gastrectomy After Systemic Therapy will improve survival time for metastasis gastric cancer compared to Systemic Therapy alone.

Conditions

  • Metastatic Gastric Cancer
  • Gastric Cancer
  • Systemic Therapy
  • Cytoreductive Gastrectomy

Interventions

PROCEDURE

Cytoreductive Gastrectomy

The patients undergo gastrectomy after 4 cycles of systemic therapy

Sponsors & Collaborators

  • University Medical Center Ho Chi Minh City (UMC)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2027-07-10
Completion
2027-12-10

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06768463 on ClinicalTrials.gov